BioSpace News Archive

Using the SRT vector and myelosuppressive preparation therapy, Memorial Sloan Kettering (“MSK”) reported encouraging results in Nature Medicine, [Boulad, F., Maggio, A., Wang, X. et al. Lentiviral globin gene therapy with reduced-intensity conditioning in adults with β-thalassemia: a phase 1 trial.

Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), today announced that the first patient has been treated in its Phase 1b open-label, proof-of-concept study of CLBS201 for the treatment of diabetic kidney disease (“DKD”) at the Clinical Advancement Center in San Antonio, Texas.

Cocrystal Pharma, Inc. (Nasdaq: COCP) (“Cocrystal” or the “Company”) reported preliminary results of a Phase 1 study with CC-42344, demonstrating a favorable safety and pharmacokinetic profile.

QSAM Biosciences Inc. (OTCQB: QSAM), announced today that the Japan Patent Office has granted a key patent that protects the use of “lower specific activity” Samarium-153 in conjunction with the treatment of bone cancer in children and adults.

MediWound Ltd., a fully-integrated biopharmaceutical company focused on next-generation biotherapeutic solutions for tissue repair and regeneration, announced that clinical data from the Company’s EscharEx® phase 2 trials was highlighted in a poster and oral presentation at the 35th Symposium on Advanced Wound Care Spring Conference.

Enteris BioPharma, Inc. announced today that two submitted abstracts were accepted for poster presentations at the 104th annual meeting of The Endocrine Society (ENDO 2022) taking place June 11-14, 2022, in Atlanta, Georgia.

AtriCure Launches EnCompass ® Clamp, a part of Isolator Synergy™ Ablation System.

Curie AI today announced the closing of a seed round from investors that include ResMed, Factory and SeedToB .

April 12, 2022 12:00 UTC ATCC to provide biological resources and services to the scientific community, as well as modify specific cell lines for African Swine Fever Virus vaccine research and production. MANASSAS, Va.--( BUSINESS WIRE )-- ATCC , the world’s premier biological materials management and standards organization, today announced that it has been awarded two projects, with a combined value of $385,000, by the United States Department of Agriculture (USDA) to sup

Nascent Biotech has partnered with BioTools, Inc to clearly define PTB’s higher order molecular structure (HOS). Nascent is exploring the potential of modifying the antibody to enhance its effectiveness and to broaden its therapeutic application.